You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES

HIGHLIGHTS

CORPORATE

Kedrion Biopharma runner up at the Premio Equita for the bond issued in July 2017

The prize is awarded to the companies that made the best use of the capital markets

read more 

CORPORATE

Kedrion Biopharma joins Columbia University to celebrate 50 years of Anti-D

Since 1968, billions of babies have been saved from Hemolytic Disease of the Fetus and Newborn

read more 

CORPORATE

Hemophilia: Kedrion signs on to groundbreaking PARTNERS programme

Goal is to improve access to replacement therapies for coagulation disorders in Europe

read more 
  1. EVENTS - 07-12-2015

    Hemophilia A. SIPPET study selected by the American Society of Hematology

    Presented at the ASH Congress in Orlando, it was chosen from amongst approximately three thousand studies

    read more 
  2. EVENTS - 09-11-2015

    Kedrion among the key players of Farmindustria's roadshow in Siena

    The Lucca-based company presented as one of the innovative pharmaceutical companies in Tuscany

    read more 
  3. CORPORATE - 12-10-2015

    Kedrion supports Fondazione Paracelso's activities in Afghanistan

    Kedrion confirms its commitment to broaden access to hemophilia treatments in developing Countries

    read more 
  4. CORPORATE - 29-09-2015

    Kedrion Notes 2019 Tender Offer results

    Kedrion has accepted for purchase Notes validly tendered for a total aggregate principal amount equal to €150,716,000

    read more 

Pages

For more information please contact: pressoffice@kedrion.com